| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AFJKAimei Health Technology Co., Ltd | 346.43M | 56.59 | 202.11 | 3.35% | 0.00 | |||
| OACCOaktree Acquisition Corp. III Life Sciences | 210.59M | 10.65 | 196.40 | 0% | 0.00 | |||
| OACCWOaktree Acquisition Corp. III Life Sciences | 0.93 | 17.12 | 0.71% | 0.00 | ||||
| DMAADrugs Made In America Acquisition Corp. Ordinary Shares | 348.41M | 10.40 | -185.63 |
| Dec 2024 | |
|---|---|
| Net Interest Income | 1.59M |
| NII Growth % | - |
| Net Interest Margin % | - |
| Interest Income | 1.59M |
| Interest Expense | 0 |
| Loan Loss Provision | 0 |
| Non-Interest Income | -1.59M |
| Non-Interest Income % | - |
| Total Revenue | 0 |
| Revenue Growth % | - |
| Non-Interest Expense | 704 |
| Efficiency Ratio | - |
| Operating Income | -703 |
| Operating Margin % | - |
| Operating Income Growth % | - |
| Pretax Income | 2.66K |
| Pretax Margin % | - |
| Income Tax | 0 |
| Effective Tax Rate % | - |
| Net Income | 2.66K |
| Net Margin % | - |
| Net Income Growth % | - |
| Net Income (Continuing) | 2.66K |
| EPS (Diluted) | 0.05 |
| EPS Growth % | - |
| EPS (Basic) | 0.05 |
| Diluted Shares Outstanding | 24.58M |
| Dec 2024 | |
|---|---|
| Cash & Short Term Investments | 1000K |
| Cash & Due from Banks | 1.36M |
| Short Term Investments | 0 |
| Total Investments | 193.58M |
| Investments Growth % | - |
| Long-Term Investments | 193.58M |
| Accounts Receivables | 0 |
| Goodwill & Intangibles | - |
| Goodwill | 0 |
| Intangible Assets | 0 |
| PP&E (Net) | 0 |
| Other Assets | 113.28K |
| Total Current Assets | 1.56M |
| Total Non-Current Assets | 193.69M |
| Total Assets | 195.25M |
| Asset Growth % | - |
| Return on Assets (ROA) | 0% |
| Accounts Payable | 0 |
| Total Debt | 11.82K |
| Net Debt | -1.35M |
| Long-Term Debt | 0 |
| Short-Term Debt | 11.82K |
| Other Liabilities | 7.02M |
| Total Current Liabilities | 727.32K |
| Total Non-Current Liabilities | 7.02M |
| Total Liabilities | 7.75M |
| Total Equity | 187.5M |
| Equity Growth % | - |
| Equity / Assets (Capital Ratio) | - |
| Return on Equity (ROE) | 0% |
| Book Value per Share | 7.63 |
| Tangible BV per Share | - |
| Common Stock | 193.58M |
| Additional Paid-in Capital | 0 |
| Retained Earnings | -6.08M |
| Accumulated OCI | 0 |
| Treasury Stock | 0 |
| Preferred Stock | 0 |
| Dec 2024 | |
|---|---|
| Cash from Operations | -89.69K |
| Operating CF Growth % | - |
| Net Income | 2.66K |
| Depreciation & Amortization | 0 |
| Deferred Taxes | 0 |
| Other Non-Cash Items | -91.72K |
| Working Capital Changes | -629 |
| Cash from Investing | -191.99M |
| Purchase of Investments | -191.99M |
| Sale/Maturity of Investments | 0 |
| Net Investment Activity | - |
| Acquisitions | 0 |
| Other Investing | 0 |
| Cash from Financing | 193.44M |
| Dividends Paid | 0 |
| Share Repurchases | 0 |
| Stock Issued | 193.99M |
| Net Stock Activity | - |
| Debt Issuance (Net) | -551.14K |
| Other Financing | 0 |
| Net Change in Cash | 1.36M |
| Exchange Rate Effect | 0 |
| Cash at Beginning | 0 |
| Cash at End | 1.36M |
| Interest Paid | 0 |
| Income Taxes Paid | 0 |
| Free Cash Flow | -179 |
| FCF Growth % | - |
| Metric | 2024 |
|---|---|
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Net Interest Margin | 0.81% |
| Equity / Assets | 96.03% |
| Book Value / Share | 7.63 |
Oaktree Acquisition Corp. III Life Sciences (OACC) has a price-to-earnings (P/E) ratio of 196.4x. This suggests investors expect higher future growth.
Oaktree Acquisition Corp. III Life Sciences (OACC) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Oaktree Acquisition Corp. III Life Sciences (OACC) is profitable, generating $5.2M in net income for fiscal year 2024.
Oaktree Acquisition Corp. III Life Sciences (OACC) has a return on equity (ROE) of 0.0%. This is below average, suggesting room for improvement.
Oaktree Acquisition Corp. III Life Sciences (OACC) has a net interest margin (NIM) of 0.8%. NIM has been under pressure due to interest rate environment.
Oaktree Acquisition Corp. III Life Sciences (OACC) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.